What is Sight Sciences?
Founded in 2010 and headquartered in Menlo Park, California, Sight Sciences Inc. operates within the ophthalmic medical device sector. The company is dedicated to creating and bringing to market advanced surgical and nonsurgical solutions aimed at addressing a range of eye diseases. Its product pipeline focuses on improving patient outcomes and offering less invasive treatment options, positioning it as a key innovator in a field with significant unmet clinical needs.
How much funding has Sight Sciences raised?
Sight Sciences has raised a total of $181.9M across 8 funding rounds:
Series A
$6.9M
Series B
$7M
Series C
$10M
Series D
$31M
Stock Offering
$30M
Debt
$2M
Series E
$30M
Debt
$65M
Series A (2015): $6.9M with participation from Scientific Health Development Partners and Allegro Investment Fund
Series B (2016): $7M led by Allegro Investment Fund, Scientific Health Development Partners, and Hicks Equity Partners
Series C (2017): $10M supported by Allegro Investment Fund
Series D (2019): $31M, investors not publicly disclosed
Stock Issuance/Offering (2020): $30M backed by D1 Capital Partners
Debt (2020): $2M with participation from PPP
Series E (2021): $30M led by D1 Capital Partners
Debt (2024): $65M supported by Hercules Capital
Key Investors in Sight Sciences
Hercules Capital
Hercules Capital is a specialty finance company focused on providing senior secured venture growth loans to high-growth, innovative venture capital-backed companies in a broad variety of technology, life sciences and sustainable and renewable technology industries.
Allegro Investment Fund
Allegro Investment Fund is a private investment vehicle that provides strategic and financial support to talented, entrepreneurial businesses, aiming to create a lasting, positive impact. With 25 years of experience and $750 million under management, the fund focuses on investments ranging from $10 million to $50 million.
Scientific Health Development Partners
Scientific Health Development (SHD) is a Dallas-based venture capital firm established in 2006 that specializes in investing in early-stage medtech companies in the U.S. The firm targets companies that address unmet clinical needs with easily adoptable technologies aimed at enhancing patient outcomes while reducing economic burdens.
What's next for Sight Sciences?
With a history of consistent capital raises, including significant debt financing and equity rounds, Sight Sciences is well-positioned for continued expansion and product development. The recent major strategic investment, coupled with the overall $181.9M in backing, suggests a trajectory towards scaling operations, further research, and broader market penetration. This strategic financing will likely fuel the company's efforts to enhance its existing portfolio and potentially explore new therapeutic areas within ophthalmology, solidifying its role as a leader in eye care innovation.
See full Sight Sciences company page
